

Mitochondrial Testing

Academy of Nutritional Medicine
with Gilian Crowther, Director of Research, AONM
30th October 2024

<https://aonm.org/mitochondrial-testing/>


Copyright MMD/AONM, All rights reserved

Mitochondrial testing with AONM/MMD

- 1. Brief introduction to the mitochondria**
- 2. ATP Profile: Total ATP, Mitochondrial ATP, Glycolytic ATP, Reserve Capacity**
- 3. Mitochondrial Health Index:**
Basal respiration rate, mitochondrial ATP turnover, proton leak, maximum respiration rate, reserve capacity, non-mitochondrial rate, calculation of the overall Mitochondrial Health Index
- 4. Supplementary biomarkers:**
Ratio of mtDNA to nDNA (mtDNA:nDNA)
PGC-1 α
Nrf-2
Mitochondrial 4977 deletion mutant (mt4977del)
Lactate/pyruvate ratio
Mitochondrial Fuel Pathways
OxPhos

XXX
Max-Mustermann Straße 5
xxx Berlin

MMD



MMD GmbH & Co. KG

Breiter Weg 10a
39104 Magdeburg
Prof. Dr. Brigitte König
CEO/ Scientific Director
Prof. Dr. Gerhard Jorch
Medical Director

Tel. office: +49 391 535 37 97
Tel. laboratory: +49 391 611 72 09
Fax: +49 391 535 38 45
E-Mail: info@mmd-web.de
Web: www.mmd-web.de

| | | | |
|----------------|---------------------|-------------------|--------------------------|
| Patient | AW | Date of birth | 01.01.1990 |
| | | Entry on | 23.07.2021 |
| Order No.: | | | |
| Date of sample | 22.07.2021 | Validated by | Prof. Dr. Brigitte König |
| Sample type | CPDA vacutainer | Cell type | PBMC |
| Results status | Final report | Results status on | 23.07.2021 |

ATP profile

| Test | Result | Unit | Reference range | Result [%] |
|----------------------------|--------|-----------|-----------------|------------|
| Total ATP | 0.8 | fmol/cell | | |
| Mitochondrial ATP capacity | 0.4 | fmol/cell | | 50 |
| Glycolytic ATP capacity | 0.5 | fmol/cell | | 63 |
| Reserve ATP capacity | 0.10 | fmol/cell | | 13 |

Reference range total ATP

| | | | | | | | | | |
|-----------|------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| fmol/cell | <0.8 | 0.8 - 1.0 | 1.0 - 1.2 | 1.2 - 1.4 | 1.4 - 1.6 | 1.6 - 2.0 | 2.0 - 2.5 | 2.5 - 3.0 | 3.0 - 5.0 |
|-----------|------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|

Reference range mitochondrial ATP capacity

| | | | | | |
|-----------|------|-----------|-----------|-----------|------|
| fmol/cell | <0.8 | 0.8 - 1.0 | 1.0 - 1.2 | 1.2 - 1.4 | >1.4 |
|-----------|------|-----------|-----------|-----------|------|

Reference range glycolytic ATP capacity

| | | | | | |
|-----------|------|-----------|-----------|-----------|------|
| fmol/cell | <0.8 | 0.8 - 1.0 | 1.0 - 1.2 | 1.2 - 1.4 | >1.4 |
|-----------|------|-----------|-----------|-----------|------|

Reference range reserve ATP capacity

| | | | | | | | | | |
|-----------|------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|------|
| fmol/cell | <0.2 | 0.2 - 0.3 | 0.3 - 0.4 | 0.4 - 0.6 | 0.6 - 0.9 | 0.9 - 1.0 | 1.0 - 1.2 | 1.2 - 1.5 | >1.5 |
|-----------|------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|------|

Total ATP

ATP profile

| Test | Result | Unit | Reference range | Result [%] |
|-----------|--------|-----------|-----------------|------------|
| Total ATP | 0.8 | fmol/cell | | |

| Reference range total ATP |
|--|
| fmol/cell |
| <0.8 0.8 - 1.0 1.0 - 1.2 1.2 - 1.4 1.4 - 1.6 1.6 - 2.0 2.0 - 2.5 2.5 - 3.0 3.0 - 5.0 |

Total ATP

This is the quantity of ATP that the cells produce at rest via both mitochondrial and non-mitochondrial pathways. Total ATP is all the adenosine triphosphate (our cells' energy currency) available to the cell. This makes it possible to assess the relative performance of mitochondrial respiration (mitochondrial ATP capacity) versus anaerobic glycolysis (glycolytic ATP capacity).

Mitochondrial and glycolytic ATP capacity

| Test | Result | Unit | Reference range | Result [%] |
|----------------------------|--------|-----------|-----------------|------------|
| Mitochondrial ATP capacity | 0.4 | fmol/cell | | 50 |

Reference range mitochondrial ATP capacity

| | | | | | |
|-----------|------|-----------|-----------|-----------|------|
| fmol/cell | <0.8 | 0.8 - 1.0 | 1.0 - 1.2 | 1.2 - 1.4 | >1.4 |
|-----------|------|-----------|-----------|-----------|------|

Mitochondrial ATP capacity measures the capacity to synthesise adenosine triphosphate (ATP) in the patient's mitochondria in a defined basal state. This is calculated by determining the absolute ATP production that is inhibited by addition of the ATP synthase inhibitor oligomycin (see figure above).

| | | | | |
|-------------------------|-----|-----------|--|----|
| Glycolytic ATP capacity | 0.5 | fmol/cell | | 63 |
|-------------------------|-----|-----------|--|----|


Reference range glycolytic ATP capacity

| | | | | | |
|-----------|------|-----------|-----------|-----------|------|
| fmol/cell | <0.8 | 0.8 - 1.0 | 1.0 - 1.2 | 1.2 - 1.4 | >1.4 |
|-----------|------|-----------|-----------|-----------|------|

ATP can also be produced in the cytosol, outside the mitochondria (though still inside the cell). This parameter measures the glycolytic capacity for ATP production: the maximum quantity of ATP that the cells are able to produce at rest via non-mitochondrial pathways, i.e. anaerobic glycolysis. This makes it possible to assess the relative performance of anaerobic glycolysis versus mitochondrial respiration. It is important to have a high glycolytic capacity in the cells so that sufficient precursors for the Krebs Cycle can be made to then be cycled into the ETC, and also so that the cytosolic production of ATP (glycolysis) can be upregulated if needed, when immune cells need to address pathogens, etc.

Reserve ATP capacity

ATP profile

| Test | Result | Unit | Reference range | Result [%] | | | | | |
|---|--------|-----------|---|------------|-----------|-----------|-----------|-----------|------|
| Reserve ATP capacity | 0.10 | fmol/cell |  | 13 | | | | | |
| Reference range reserve ATP capacity | | | | | | | | | |
| fmol/cell | <0.2 | 0.2 - 0.3 | 0.3 - 0.4 | 0.4 - 0.6 | 0.6 - 0.9 | 0.9 - 1.0 | 1.0 - 1.2 | 1.2 - 1.5 | >1.5 |

ATP synthesis is generally presumed to be coupled almost entirely to two metabolic processes: oxidative phosphorylation and glycolysis. There is however another essential metabolic process that interconverts the three adenine nucleotides (ATP, ADP and AMP) using adenylate kinase according to metabolic needs. Adenylate kinase catalyses a reversible reaction: $2 \text{ADP} \rightleftharpoons \text{ATP} + \text{AMP}$. This is a vital factor in regulating the energy charge in cells, providing an open system able to accept, store and supply energy to cells as needed. The marker “Reserve ATP capacity” indicates how dynamically the cell is able to perform this catalytic interconversion.


Here, the reserve ATP capacity is 13 %/ 0.10 fmol/ cell. The patient's result is in the very low range. The optimal would be between 0.6 to 0.9 fmol/cell. 13 % means that the cell is unable to perform dynamic catalytic interconversion between the three adenine nucleotides (ATP, ADP and AMP) according to metabolic needs.

Impaired glycolytic ATP capacity: Could insulin resistance be an issue? In 95% of the US population, Dr. Pizzorno said recently*


Insulin plays a significant role in this array of glycolysis regulation. In the short term, insulin, through insulin signaling pathways controls glucose entry and regulates the levels of F-2,6-P₂, a key regulator of glycolysis.

ScienceDirect.com
<https://www.sciencedirect.com/article/abs/pii/>

Regulation of glycolysis—role of insulin - ScienceDirect.com



Scheme outlining insulin signaling and the regulation of glycolysis. In various tissues, insulin controls distinct components of glycolysis. IR, insulin receptor; IRS, insulin receptor substrate; PI3K, phosphatidylinositol-3-kinase; PIP2, phosphatidylinositol-4,5-phosphate; PIP3, phosphatidylinositol-3,4,5-phosphate; GLUT4, glucose transport 4; and PDK, phosphatidylinositol-dependant kinase.




[Download: Download full-size image](#)

Figure 1. Major steps of glycolysis. Glycolysis is the pathway for the generation of pyruvate/lactate from glucose. Depending on cell types in which glycolysis occurs, glucose uptake is mediated mainly by glucose transporter 2 (GLUT2) or GLUT4. Following glucose uptake, rates of glycolysis are determined at steps of glucose phosphorylation, which is catalyzed by hexokinase II or hexokinase IV (glucokinase, GK), and the generation of fructose-1,6-bisphosphate, which is catalyzed by 6-phosphofruktose-1-kinase (6PFK1). The latter is activated by fructose-2,6-bisphosphate (F2,6P₂), whose production is controlled by 6-phosphofruktose-2-kinase/fructose-2,6-bisphosphatase (6PFK2/FBPase2). DHAP, dihydroxyacetone phosphate; TCA, tricarboxylic acid cycle.

Source: 1. Wu C, Khan SA, Lange AJ. Regulation of glycolysis-role of insulin. *Exp Gerontol.* 2005 Nov;40(11):894-9;


2. Hers HG. Mechanisms of blood glucose homeostasis. *J Inher Metab Dis.* 1990;13(4):395-410; Nutrition Medicine Institute (NMI) Summit, London, "Mitochondrial Nutrition for Energy, the Brain, and Healthy Ageing" < Oct. 11/12, 2024


Impaired glycolytic ATP capacity: Cofactors may be lacking to get pyruvic acid into the mitochondria



Source: @Genova Diagnostics ▪ A.L. Peace-Brewer, PhD, D(ABMLI), Lab Director ▪ CLIA Lic. #34D0655571 ▪ Medicare Lic #34-8475 (with permission)

If mitochondrial ATP capacity on the ATP profile is stronger: fatty acids are getting in


Mitochondrial ATP capacity **1.33** fmol/cell  **84**

Glycolytic ATP capacity **1.12** fmol/cell  **70**

Oxidative Stress & Mitochondrial Dysfunction

Then this entry point is working better

Carnitine!



There are however mitochondrial fatty acid oxidation disorders (FAODs) (inherited metabolic diseases) that affect the transport of fatty acids into mitochondria:

- Carnitine transporter defect
- Carnitine-acylcarnitine translocase (CACT) deficiency
- LCHAD deficiency
- Etc.

Mitochondrial testing with AONM/MMD

- 1. Brief introduction to the mitochondria**
- 2. ATP Profile:** Total ATP, Mitochondrial ATP, Glycolytic ATP, Reserve Capacity
- 3. Mitochondrial Health Index:**
Basal respiration rate, mitochondrial ATP turnover, proton leak, maximum respiration rate, reserve capacity, non-mitochondrial rate, calculation of the overall Mitochondrial Health Index
- 4. Supplementary biomarkers (next time!):**
Ratio of mtDNA to nDNA (mtDNA:nDNA)
PGC-1 α
Nrf-2
Mitochondrial 4977 deletion mutant (mt4977del)
Lactate/pyruvate ratio
Phase 2:
Number of mitochondria
Intact mitochondria versus Non-intact mitochondria

Mitochondrial Health Index: top page

Requisition: Mitochondrial Health Index / PBMCs

Sample type: Blood in CPDA vials

Summary

| | Patient's value | Target value (optimal) |
|--|--|------------------------|
| Mitochondrial Health Index (MHI) | 0.00 | >2.5 |
| Mitochondrial Bioenergetics | | |
| Coupling efficiency, % | 86 | 90-95 |
| Reserve respiration capacity, % | 0 | >400 |
| Cellular oxygen consumption profile | | |
| Non-mitochondrial respiration as a share of total respiration, % | 32 | <10 |
| Proton leak as a share of total respiration, % | 10 | 5-10 |
| Share of respiration used for mitochondrial ATP generation, % | 58 | >90 |
| ATP turnover rate (mitochondrial oxygen utilisation) | | |
| ATP base turnover, % | 100 | <20 |
| ATP reserve, % | 0 | >80 |
| Basal oxygen consumption rate in pmol oxygen/min | 28.75 | |
| Potential maximum oxygen consumption rate in pmol oxygen/min | 22 | >500 |
| Cellular energy phenotype | | |
| At rest | Resting | Resting |
| On energy demand | Resting | Energetic/Aerobic |
| Metabolic potential, mitochondrial percentage | 84 | >350 |
| Metabolic potential, glycolysis percentage | 151 | >350 |
| Oxygen consumption/glycolysis on energy demand | Strong preference for anaerobic glycolysis | |

| | | | | |
|---------|---------------------|---------------------|---------------|--------------------|
| Optimal | Slightly high / low | Moderately high/low | Very high/low | Extremely high/low |
|---------|---------------------|---------------------|---------------|--------------------|

Summary relating to mitochondrial dysfunction: selected markers

| | None | Slight | Moderate | Considerable | Extreme | |
|---|------|--------|-----------|--|---------|-----------|
| Mitochondrial dysfunction | | | | | ✓ | |
| Cellular imbalance | | | | ✓ | | |
| Indications of | | | | | | |
| Increased formation of oxygen radicals in the cell | | ✓ | No Yes | Insufficient ATP formation on energy demand | ✓ | No Yes |
| Increased formation of oxygen radicals in the mitochondria | | ✓ | No Yes | Limited glucose utilisation | | No Yes |
| Restricted function of the electron transport chain in the mitochondria | | ✓ | No Yes | Limited fatty acid oxidation | | No Yes |
| Limited number of functionally intact mitochondria | | ✓ | No Yes | Acute inflammation, active chronic inflammation/ autoimmune disease | ✓ | No Yes |

Further diagnostic opportunities for personalised therapy

Investigate minerals and further mitochondrial cofactors

Investigate mitochondrial mass (mtDNA:nDNA/number of mitochondria) and analyse mitochondrial mutations that influence ATP generation (e.g., the common deletion mt4977bp).

- Upregulated ROS in the cells
- Compromised function of the electron transport chain
- Limited no. of functionally intact mitochondria
- Insufficient ATP on demand

Comparison of various tests

Patient: xxxxxxxx
 Date of birth: 19.07.1941
 Sample taken: 15.06.2021
 Receipt of sample: 16.06.2021
 Test completed: 16.06.2021
 Final result: 16.06.2021
 Validated by: Prof. Dr. Brigitte König
 Medical Director: Prof. Dr. Gerhard Jorch

Comparison with previous values

| | 28.10.2020 | 19.05.2021 | Current value 16.06.2021 | Target value (optimal) |
|--|--|--|--|------------------------|
| Mitochondrial Health Index (MHI) | 1.87 | 1.54 | 1.90 | >2.5 |
| Mitochondrial bioenergetics | | | | |
| Coupling efficiency, % | 94.76 | 84.62 | 93.80 | 100 |
| Reserve respiration capacity, % | 242.93 | 291.35 | 468.73 | >400 |
| Cellular oxygen consumption profile | | | | |
| Non-mitochondrial respiration as a share of total respiration, % | 33.66 | 32.09 | 35.32 | <10 |
| Proton leak as a share of total respiration, % | 3.76 | 10.45 | 4.96 | |
| Share of respiration for mitochondrial ATP generation, % | 62.58 | 57.46 | 59.72 | >90 |
| ATP turnover rate (mitochondrial oxygen utilisation) | | | | |
| ATP base turnover, % | 27.35 | 21.62 | 16.30 | <20 |
| ATP reserve, % | 72.65 | 78.38 | 83.70 | >80 |
| Maximum possible oxygen consumption rate, pmol oxygen/min | 90.78 | 123.10 | 180.06 | >300 |
| Cellular energy phenotype | | | | |
| At rest | Resting | Resting | Resting | Resting |
| On energy demand | Energetic | aerobic | aerobic | Energetic/aerobic |
| Metabolic potential, % - Mitochondria | 262.44 | 297.81 | 401.74 | >350 |
| Metabolic potential, % - glycolysis | 312.43 | 252.29 | 334.84 | >350 |
| Oxygen consumption/glycolysis ratio on energy demand | Slight preference for anaerobic glycolysis | Slight preference for the mitochondria | Slight preference for the mitochondria | |



Maximum possible oxygen consumption rate has doubled; many markers are showing improvement

Mitochondrial testing with AONM/MMD

- 1. ATP Profile:** Total ATP, Mitochondrial ATP, Glycolytic ATP, Reserve Capacity
- 2. Mitochondrial Health Index:**
Basal respiration rate, mitochondrial ATP turnover, proton leak, maximum respiration rate, reserve capacity, non-mitochondrial rate, calculation of the overall Mitochondrial Health Index
- 3. Supplementary biomarkers:**
Ratio of mtDNA to nDNA (mtDNA:nDNA)
PGC-1 α
Nrf-2
Mitochondrial 4977 deletion mutant (mt4977del)
Lactate/pyruvate ratio

Mitochondria have their own DNA

mtDNA:nDNA



Source: MMD GmbH & Co KG Author Prof. Dr. Brigitte König; Hoffmann A, Spengler D. The Mitochondrion as Potential Interface in Early-Life Stress Brain Programming. Front Behav Neurosci. 2018 Dec 6;12:306; https://en.wikipedia.org/wiki/Mitochondrial_DNA: Images free to use under Commons License


Ratio of mitochondrial DNA to nuclear DNA shows the mitochondrial mass in the cell

mtDNA:nDNA

DNA tests:

Ratio of mitochondrial DNA to nuclear DNA

Example 1:



The ratio of mitochondrial DNA to nuclear DNA is normal, though towards the lower end of the reference range.

Nuclear DNA remains stable at a unit of 1, but mitochondrial DNA will increase proportionally to the number of mitochondria in the cell.

It is important to note though that this does not mean that the mitochondria being detected are healthy/intact.

mtDNA:nDNA – numbers pathologically high/low

mtDNA:nDNA

Example 2:

Ratio mtDNA:nDNA **1039**
Number of mitochondrial DNA copies per 1 copy of nuclear DNA




Example 3:

ratio mtDNA:nDNA **115**
Number of mitochondrial DNA copies per 1 copy of nuclear DNA



Reference range ratio mtDNA:nDNA



Too high (see example 2):

The cell is trying to counteract the lack of energy by increasing the number of mitochondria.

Too low (see example 3):

The cell is unable to counteract the lack of energy by increasing the number of mitochondria.

PGC-1-alpha is central for the induction of new mitochondria

PGC-1-alpha




FIGURE 2 | Mitochondrial biogenesis pathways: When PGC-1 α is activated, PGC-1 α activates NRF1 and NRF2, and subsequently TFAM, which regulate genes involved in subunits of mitochondrial respiratory chain complexes, import of nuclear-encoded mitochondrial proteins, and mtDNA replication and transcription. 1

- PGC-1 α regulates mitochondrial biogenesis but also has effects on mitochondrial functions beyond biogenesis.
- Mitochondrial quality control mechanisms, including fission, fusion, and mitophagy, are regulated by PGC-1 α .
- PGC-1 α -mediated regulation of mitochondrial quality may affect age-related mitochondrial dysfunction and insulin sensitivity. 2

The test for PGC-1-alpha measures its relative expression

PGC-1-alpha

RNA profile

| Test | Unit | Result |
|-------------|-----------------------------------|----------|
| PGC-1-alpha | Relative expression (to GAPDH) | 0.000953 |

GAPDH: glyceraldehyde-3-phosphate dehydrogenase



Interpretation: "Basic values of the peripheral blood leucocytes"

PGC-1-alpha expression is barely detectable. This indicates extremely low/absent new mitochondrial formation.

If this is the case, and mtDNA:nDNA is low too, then initiatives should be taken to increase PGC-1-alpha (*list of inducers available*)

The “common deletion” mDNA⁴⁹⁷⁷ is caused by oxidative stress

Oxidative stress



Nucleic Acids Research

Issues Section browse Advance articles Submit Purchase About Nucleic Acids Research



Volume 37, Issue 8
1 May 2009

Article Contents

- Abstract
- INTRODUCTION
- MATERIALS AND METHODS
- RESULTS
- DISCUSSION
- FUNDING
- ACKNOWLEDGEMENTS
- REFERENCES

JOURNAL ARTICLE

Oxidative stress induces degradation of mitochondrial DNA

Inna Shokolenko, Natalia Venediktova, Alexandra Bochkareva, [Glenn L. Wilson](#), Mikhail F. Alexeyev

Nucleic Acids Research, Volume 37, Issue 8, 1 May 2009, Pages 2539–2548,
<https://doi.org/10.1093/nar/gkp100>

Published: 05 March 2009 Article history


PDF Split View Cite Permissions Share

Abstract

Mitochondrial DNA (mtDNA) is located in close proximity of the respiratory chains, which are the main cellular source of reactive oxygen species (ROS). ROS can induce oxidative base lesions in mtDNA and are believed to be an important cause of the mtDNA mutations, which accumulate with aging and in diseased states. However, recent studies indicate that cumulative levels of base substitutions in mtDNA can be very low even in old individuals. Considering the reduced complement of DNA repair pathways available in mitochondria and higher susceptibility of mtDNA to oxidative damage than nDNA, it is presently

This can be measured, and shows the degree of oxidative stress the mitochondria are suffering ...

Oxidative stress



Before deletion
Wildtype mtDNA = 16569 base pairs

After deletion
mtDNA = 11562 base pairs

... as well as any damage to mitochondrial DNA

Deletion mutant 4977

Oxidative stress

Example 1:

Mitochondrial 4977 Deletion mutant
(mt4977del)

1.03E+06



Number of copies of non-mutated mtDNA to 1 copy mt4977del


Reference range mt4977del



The mitochondrial deletion mutant mt4977bp is noticeably enhanced. This indicates oxidative stress and damage to mitochondrial DNA.

Among mtDNA deletions, one of the most vital that causes huge destruction of almost one third in length of the mitochondrial genome is the 4977-bp mtDNA deletion (mDNA⁴⁹⁷⁷). This is one of the best-described large-scale mtDNA deletions, and has been found to accumulate in numerous disorders (literature available upon request). It is often known as a “common deletion” due to the frequency with which it has been reported. The deleted region encodes seven polypeptides essential for the OXPHOS pathway: four for Complex I, one for Complex IV, and two for Complex V. **This can cause complete failure of ATP production in the mitochondria affected.**

One initiative is to check Nrf-2: our cells' master antioxidant regulator



Nrf-2

“Nuclear factor-erythroid factor 2-related factor 2 (Nrf2) is a critical transcription factor that regulates the expression of over 1000 genes in the cell under normal and stressed conditions. Nrf2 has been historically considered as a crucial regulator of antioxidant defense to protect against various insult-induced organ damage”

Problem if it is undetectable and you have evident oxidative stress

RESULTS

Nrf-2

Sample type: Blood in CPDA vials

Requisition:
RNA

Summary

RNA profile

| Test | Unit | Result |
|--|-----------------------------------|----------------|
| Nrf-2 | Relative expression (to GAPDH) | Not detectable |
| GAPDH: glyceraldehyde-3-phosphate dehydrogenase | | |


Interpretation: "Basic values of the peripheral blood leucocytes"

Nrf-2 expression is not detectable, indicating extremely low/absent defence against reactive oxygen metabolites in the cell.

Nrf-2


NRF-2, nuclear factor erythroid 2-related factor 2, is the master regulator of our antioxidant system to protect cells from reactive oxygen species. Nrf-2 activates Phase II detoxification – particularly glutathione-S-transferase and other antioxidant enzymes, including SOD-2, catalase and glutathione peroxidase. It is crucial to have adequate levels of this in the mitochondria.

This test of mitochondrial oxidation levels can also be done as a fingerprick test



Simple, can be done as a follow-up, or to check on your physical workup regime: are you over-training?

Pyruvate is the pathway into the mitochondria, as you will remember



Lactate/Pyruvate Index: shows what nutrients are being used as fuel for the mitochondria

Lactate/Pyruvate
Plus

The higher the value of lactate compared to pyruvate, the more glycolysis is occurring. A higher level of pyruvate compared to lactate is a prerequisite for successful transfer of substrates in the mitochondria for oxidative phosphorylation.

The normal range for immune cells usually ranges from 1.0 – 0.7. Examples are calculated below

| Ratio | Basal metabolic rate |
|------------|--|
| >2.0 | The cell is primarily using carbohydrates and preferentially converting them to lactate. |
| >1.2 – 2.0 | The cell is primarily using carbohydrates and partially converting them to lactate. |
| 1 – 1.2 | The cell is primarily using carbohydrates and transporting them into the mitochondria. |
| 0.8 – 1.0 | The cell is using carbohydrates, fatty acids and amino acids. The carbohydrates are primarily being transported into the mitochondria. |
| <0.8 | The cell is primarily using fatty acids as fuel. |

Lactate/Pyruvate Index: shows what macronutrients are being used as fuel for the mitochondria

Cell type:

Peripheral blood mononuclear cells (PBMC)

Lactate/Pyruvate Plus

Lactate/Pyruvate ratio PLUS

| Test | Result | Interpretation |
|-------------------------------------|--------|---|
| Lactate/Pyruvate in dormant cells | 1.61 | Your immune cells are primarily metabolising carbohydrates and partially (30%) converting them to lactate |
| Lactate/Pyruvate in activated cells | 2.43 | The cells are primarily using carbohydrates and converting around 80% of them to lactate |

This result:
Under pressure, the fuel is largely not going into the mitochondria, it is being recycled into lactate. The buildup can be very painful (fibromyalgia-type symptoms).

The normal range for immune cells usually ranges from 1.0 – 0.7. Examples are calculated below

| Ratio | Basal metabolic rate |
|------------|--|
| >2.0 | The cell is primarily using carbohydrates and preferentially converting them to lactate. |
| >1.2 – 2.0 | The cell is primarily using carbohydrates and partially converting them to lactate. |
| 1 – 1.2 | The cell is primarily using carbohydrates and transporting them into the mitochondria. |
| 0.8 – 1.0 | The cell is using carbohydrates, fatty acids and amino acids. The carbohydrates are primarily being transported into the mitochondria. |
| <0.8 | The cell is primarily using fatty acids as fuel. |

| PATIENT INFORMATION | | BARCODE (Lab use only) | Please send results to: <input type="checkbox"/> myself <input type="checkbox"/> my practitioner | |
|---|----------|--|---|--------------------------------------|
| Patient FIRST NAME*: | | | Time of Blood Draw*: | ORDERING DR/PRACTITIONER INFORMATION |
| Patient SURNAME*: | | Dr. / Practitioner name: | | |
| DATE OF BIRTH (DD/MM/YYYY)*: | | Date of blood draw (DD/MM)*: | Clinic: | |
| Sex assigned at birth* (please circle): male female | | Material/Quantity <input type="checkbox"/> CPDA | Street Address: | |
| Street Address: | | | Postcode: | City: |
| Postcode: | City: | | County: | Country: |
| County: | Country: | | Tel no: | |
| Tel no: | | AONM HELPLINE: +44 (0) 3331 210 305 | Email: | |
| Email*: | | | | |

| <input checked="" type="checkbox"/> | #TEST NUMBER | NAME OF TEST | | MATERIAL | PRICE |
|-------------------------------------|--------------|--|--|----------|-------|
| <input type="checkbox"/> | M1 | ATP Profile: | Total ATP, Mitochondrial ATP, Glycolytic ATP, Reserve ATP | CPDA x1 | £125 |
| <input type="checkbox"/> | M2 | Mitochondrial Health Index (MHI): | Basal respiration rate, mitochondrial ATP turnover, proton leak, maximum respiration rate, reserve capacity, non-mitochondrial rate, calculation of the overall Mitochondrial Health Index | CPDA x1 | £195 |
| <input type="checkbox"/> | M3 (M1+M2) | Combination of ATP Profile and MHI (M1 & M2) | | CPDA x2 | £285 |

SUPPLEMENTARY BIOMARKERS ON REQUEST (can normally only be done along with the ATP Profile and/or MHI)

| | | | | | |
|--------------------------|-------------------|--|--|----------------------------|------|
| <input type="checkbox"/> | M4 | Ratio of mtDNA to nDNA | | 1 additional CPDA (max. 2) | £70 |
| <input type="checkbox"/> | M5 | PGC-1 α | | 1 additional CPDA (max. 2) | £50 |
| <input type="checkbox"/> | M6 | Nrf-2 | | 1 additional CPDA (max. 2) | £50 |
| <input type="checkbox"/> | M7 (M4-M5-M6) | Combination of Ratio of mtDNA to nDNA, PGC-1 α , and Nrf-2 (M4, M5, M6) | | 1 additional CPDA (max. 2) | £135 |
| <input type="checkbox"/> | M8 | Lactate/pyruvate ratio (must be ordered at same time as MHI) | | 1 additional CPDA (max. 2) | £70 |
| <input type="checkbox"/> | M9 | Mitochondrial 4977 deletion mutant (mt4977del) | | 1 additional CPDA (max. 2) | £70 |
| <input type="checkbox"/> | M10 (M3-M7-M8-M9) | Combination of all above (M3, M7, M8, M9) | | CPDA x2 | £485 |
| <input type="checkbox"/> | M11 | Intact vs. non-intact mitochondria (must be ordered at same time as MHI + M4 + M9) | | CPDA x2 | £25 |
| <input type="checkbox"/> | M12 | Mitochondrial Fuel Pathways (must be ordered at same time as MHI + M4 + M9) | | CPDA x2 | £195 |

Add £50 for courier delivery (to send from UK). Please Request shipping prices from elsewhere.

Tests plus courier. Total:

Tests of telomere length indicate a patient's biological (rather than chronological) age



| | |
|-------------------|--------------------------|
| Patient | |
| Geburtsdatum | 28.11.1967 |
| Probennahme | 05.03.2024 |
| Probeneingang | 06.03.2024 |
| Untersuchungsende | 02.04.2024 |
| Endbefund | 02.04.2024 |
| Validiert durch | Prof. Dr. Brigitte König |
| Ärztliche Leitung | Prof. Dr. Gerhard Jorch |



MMD GmbH & Co. KG | Breiter Weg 10 a | 39104 Magdeburg


[Clinic]

RESULTS

| | |
|--------------------------|---------------------------------|
| Sample type: Whole blood | Test requested: Telomere length |
|--------------------------|---------------------------------|

| | |
|--|---------|
| Relative telomere length (telomere to single copy gene ratio, T/S) | 0.724 |
| Absolute telomere length | 7.23 kb |
| Chronological age | 57 |
| Age calculated by telomere length, i.e. biological age | 33 |

Test results/interpretation: The calculated absolute telomere length (7.23 kilobases) corresponds to an age of between 30-35 years. The result means that the telomeres are longer than for 50% of people in the respective age group. This is a very encouraging result.



Relevance of telomere dysfunction for features of cellular aging

Fingerprick tests also available



MITOCHONDRIAL TESTS USA 3 CAPILLARY BLOOD DRAW (FINGERPRICK)

| PATIENT INFORMATION | | BARCODE (Lab use only) | Please send results to: <input type="checkbox"/> myself <input type="checkbox"/> my practitioner | |
|-----------------------------------|----------------|--|---|--|
| Patient FIRST NAME*: | | | ORDERING DR/PRACTITIONER INFORMATION | |
| Patient SURNAME*: | | Date of Fingerprick (DD/MM)*: | Dr. / Practitioner name: | |
| DATE OF BIRTH (DD/MM/YYYY)*: | | | Clinic: | |
| Sex* (please circle): male female | | Please fill 2x rings for each test, up to a total of 9 rings for ALL tests. | Street Address: | |
| Street Address: | | | ZIP: _____ City: _____ | |
| ZIP: _____ | City: _____ | | County: _____ Country: _____ | |
| County: _____ | Country: _____ | AONM HELPLINE: +44 (0) 3331 210 305 | Tel no: _____ | |
| Tel no: _____ | | | Email: _____ | |
| Email*: | | | | |

| <input checked="" type="checkbox"/> | #Test number | Name of test | Price (individual tests) | Price (ALL) |
|-------------------------------------|--------------|--|--------------------------|-------------|
| <input type="checkbox"/> | MFP1 | Oxidative stress measured using the mt4977 deletion mutant | £80 | £352 |
| <input type="checkbox"/> | M6 | Nrf-2 (Master antioxidant regulator) | £50 | |
| <input type="checkbox"/> | M15 | 8-OH-dG-DNA (a predominant ROS lesion) | £58 | |
| <input type="checkbox"/> | MFP8 | Telomere length | £149 | |
| <input type="checkbox"/> | MFP7 | Fingerprick Test Kit (incl. delivery to USA by Royal Mail) | £15 | |

Courier (shipping) costs to be determined. Tests plus courier. Total: _____

Many videos about the Seahorse technology available, and over 8,000 studies* for which the Seahorse has been used

HOW THE SEAHORSE XF WORKS




Videos are at the bottom of this page:


<https://aonm.org/mitochondrial-testing/>

SEAHORSE: ENERGY PATHWAYS

The tests require only one vial of blood in a CPDA[i] tube. The laboratory uses



* <https://www.agilent.com/search/?N=4294836537>



Thanks very much for your attention!

info@aonm.org, 0333 121 0305

gilian@aonm.org, 0786 772 6387

Copyright MMD/AONM, All rights reserved